The global type 1 diabetes market is expected to reach USD 25.52 billion by 2024

Monday, January 8, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Jan. 8, 2018 /PRNewswire/ -- Type 1 Diabetes (T1D) Market Size and Forecast, By Insulin Analog (rapid Acting, long

Acting, Premix Analogs), And Trend Analysis, 2014 - 2024Download the full report: https://www.reportbuyer.com/product/5205115 The global type 1 diabetes market is expected to reach USD 25.52 billion by 2024. A significant
increase in the prevalence of type 1 diabetes coupled with Rigorous research & development activities to introduce novel formulations drives the T1D market growth.Sedentary lifestyles, unhealthy diet habits coupled with rising obesity rates will further enhance the uptake of various types of insulin for the treatment of this disorder. Though this type of diabetes is rare still the number of cases is increasing by 3% every year according to the data enumerated by the International Diabetes Federation (IDF).Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. This affects the respective countries and their national healthcare systems. For instance, the expenditure on diabetes management accounts for around 5% to 20% of the total healthcare spending.Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the excess release of glucose in blood cells. The market penetration of long-acting insulin products is higher as compared to other two types, however, during the forecast period, the uptake and acceptance of rapid and premix analogs are anticipated to increase. The reason being the quick action and optimum performance of these two over long-acting insulin.The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total market share. The reason being extensive product offerings and continuous research and development activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies. Also, high probability of launch of several biosimilars by new entrants, major players might face competition during the forecast period.To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are continuously investing in the development of the improved versions of insulin products. For instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market.Download the full report: https://www.reportbuyer.com/product/5205115 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-global-type-1-diabetes-market-is-expected-to-reach-usd-2552-billion-by-2024-300578382.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store